Business, energy, technology, markets and global industry news from Business News Today

Oncolytics Biotech

PharmaDeviceNews Oncolytics Biotech
Representative image illustrating cancer immunotherapy research as Oncolytics Biotech reports HPV-specific immune responses and promising anal cancer activity with pelareorep.
Pharma & Biotech

Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research

Oncolytics Biotech reports HPV-specific T-cell responses with pelareorep in anal cancer. See what the new immune findings mean for treatment.

Read More
FDA written feedback supports a potential accelerated-approval strategy for Oncolytics’ REO 033 using response rate and duration, but the company must first generate supportive randomized Part A data before moving toward a pivotal expansion. Representative image.
Pharma & Biotech

Oncolytics says FDA opens a possible accelerated-approval route for pelareorep in RAS-mutant colorectal cancer

FDA written feedback supports a potential pivotal expansion of REO 033 using response rate and duration as an accelerated-approval strategy, but Oncolytics must first generate supportive randomized Part A data.

Read More
A representative image illustrating Oncolytics Biotech’s pelareorep colorectal cancer research as FDA feedback outlines a potential accelerated approval path in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Pharma & Biotech

Pelareorep gets clearer FDA path toward accelerated approval in RAS-mutant colorectal cancer

FDA feedback could let pelareorep move directly into a pivotal colorectal cancer expansion if randomized REO 033 data support accelerated approval.

Read More
Pharma & Biotech

Why Oncolytics Biotech’s new GOBLET cohort 4 data matters for third-line anal cancer immunotherapy strategies

Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.

Read More